BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 30559126)

  • 21. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
    J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
    Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
    Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Retrospective study on the efficacy and safety of low dose apatinib in reversing chemotherapy resistance in sarcoma].
    Ye T; Yuan SY; Fan L; Feng LW; Chen YT; Chen J
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(31):2435-2440. PubMed ID: 36000372
    [No Abstract]   [Full Text] [Related]  

  • 24. Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy.
    Liu Z; Ou W; Li N; Wang SY
    Thorac Cancer; 2018 Oct; 9(10):1285-1290. PubMed ID: 30126078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma.
    Tian Z; Liu H; Zhang F; Li L; Du X; Li C; Yang J; Wang J
    Invest New Drugs; 2020 Oct; 38(5):1559-1569. PubMed ID: 32100146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study.
    Tian Z; Gu Z; Wang X; Liu Z; Yao W; Wang J; Zhang P; Cai Q; Ge H
    Medicine (Baltimore); 2019 May; 98(19):e15650. PubMed ID: 31083265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.
    Liu C; Jia Q; Wei H; Yang X; Liu T; Zhao J; Ling Y; Wang C; Yu H; Li Z; Jiao J; Wu Z; Yang C; Xiao J
    Lancet Oncol; 2020 Sep; 21(9):1244-1252. PubMed ID: 32888455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of apatinib on multiple advanced-stage nongastric cancers.
    Wu X; Wang H; Wu Y; Jin J; Zhan Y; Zhu G; Zhang F; Zhang C; Gan J; Li W
    J Cancer Res Ther; 2019; 15(4):836-841. PubMed ID: 31436240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: A single-center observational study.
    Zheng K; Xu M; Wang L; Yu X
    Medicine (Baltimore); 2018 Aug; 97(31):e11734. PubMed ID: 30075583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial.
    Italiano A; Mir O; Mathoulin-Pelissier S; Penel N; Piperno-Neumann S; Bompas E; Chevreau C; Duffaud F; Entz-Werlé N; Saada E; Ray-Coquard I; Lervat C; Gaspar N; Marec-Berard P; Pacquement H; Wright J; Toulmonde M; Bessede A; Crombe A; Kind M; Bellera C; Blay JY
    Lancet Oncol; 2020 Mar; 21(3):446-455. PubMed ID: 32078813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
    Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
    Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical efficacy and safety of apatinib combined with S-1 in advanced esophageal squamous cell carcinoma.
    Zhao J; Lei J; Yu J; Zhang C; Song X; Zhang N; Wang Y; Zhang S
    Invest New Drugs; 2020 Apr; 38(2):500-506. PubMed ID: 31650447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer.
    Xu J; Liu X; Yang S; Zhang X; Shi Y
    Asia Pac J Clin Oncol; 2018 Jun; 14(3):264-269. PubMed ID: 29243413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.
    Li J; Qin S; Xu J; Guo W; Xiong J; Bai Y; Sun G; Yang Y; Wang L; Xu N; Cheng Y; Wang Z; Zheng L; Tao M; Zhu X; Ji D; Liu X; Yu H
    J Clin Oncol; 2013 Sep; 31(26):3219-25. PubMed ID: 23918952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Phase II Study of Apatinib in Patients with Chemotherapy-Refractory Esophageal Squamous Cell Carcinoma (ESO-Shanghai 11).
    Chu L; Chen Y; Liu Q; Liang F; Wang S; Liu Q; Yu H; Wu X; Zhang J; Deng J; Ai D; Zhu Z; Nie Y; Zhao K
    Oncologist; 2021 Jun; 26(6):e925-e935. PubMed ID: 33393167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients.
    Yao H; Chen X; Tan X
    BMC Cancer; 2021 Apr; 21(1):449. PubMed ID: 33892656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
    Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.
    Lin Y; Qin S; Li Z; Yang H; Fu W; Li S; Chen W; Gao Z; Miao W; Xu H; Zhang Q; Zhao X; Bao J; Li L; Ren Y; Lin C; Jing S; Ma Q; Liang J; Chen G; Zhang H; Zhang Y; Zhou X; Sang Y; Hou Z
    JAMA Oncol; 2022 Feb; 8(2):242-250. PubMed ID: 34913959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Results of a Phase II Trial of Apatinib for Progressive Radioiodine Refractory Differentiated Thyroid Cancer.
    Lin YS; Zhang X; Wang C; Liu YQ; Guan WM; Liang J
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e3027-e3036. PubMed ID: 33769497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
    Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
    Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.